2022 World Conference on Lung Cancer (ePosters)-EP08.02-156. Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US

EP08.02-156. Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US

Back to course

Pdf Summary

An analysis of real-world data on the treatment of non-small cell lung cancer (NSCLC) in patients with anaplastic lymphoma kinase gene rearrangements (ALK) identified an unmet need for effective treatments. The median real-world progression-free survival for first- and second-line ALK tyrosine kinase inhibitor (TKI) therapy was 8 months. The treatment landscape for patients with ALK NSCLC is evolving, and several new next-generation ALK TKIs have received FDA approval for first-line treatment. Comorbidities are frequent in patients with lung cancer and have an impact on diagnostic and therapeutic management. However, there are no studies that have described recent treatment patterns among patients with ALK NSCLC or assessed the impact of comorbidity burden on the treatment duration of next-generation ALK TKIs.<br /><br />This study aimed to describe treatment patterns of patients with advanced/metastatic ALK NSCLC in recent years and evaluate the impact of comorbidity burden on the duration of first-line treatment with next-generation ALK TKIs. The study used a large US claims database and included patients who received at least one ALK inhibitor after their initial advanced/metastatic lung cancer diagnosis. The comorbidity burden was evaluated using the Charlson Comorbidity Index, and the time to treatment discontinuation (TTD) of first-line next-generation ALK TKIs was analyzed.<br /><br />The results showed that most patients received next-generation ALK TKIs as first-line treatment. The median TTD stratified by comorbidity burden was not reached for patients with a CCI of 0, 26.5 months for those with a CCI of 1, and 18.5 months for those with a CCI of 2. Patients with a higher comorbidity burden had an increased risk of discontinuing first-line treatment compared to those with a lower burden. The study has some limitations, including those inherent to observational studies and the limited representativeness of the claims database.<br /><br />In conclusion, the study highlights the need for more effective treatments for patients with ALK NSCLC and the impact of comorbidity burden on treatment duration. Further evaluation of novel therapies for first-line treatment and the management of comorbidities in patients with ALK advanced/metastatic NSCLC is necessary.

Asset Subtitle

Yin Wan

Meta Tag

Speaker Yin Wan

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

non-small cell lung cancer

NSCLC

anaplastic lymphoma kinase

ALK gene rearrangements

progression-free survival

tyrosine kinase inhibitor

comorbidities

next-generation ALK TKIs

treatment patterns

Charlson Comorbidity Index